A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures

Background: This study aimed to compare the efficacy of Denosumab (DEN) versus Zoledronic acid (ZOL) in treating patients with osteoporotic vertebral compression fractures (OVCF) after percutaneous kyphoplasty (PKP). Methods: In this study, 128 OVCF patients who underwent PKP in our hospital from Ju...

Full description

Saved in:
Bibliographic Details
Main Authors: Gao Shouda, Zhang Lijun, Liu Liyan, Meng Jiayin
Format: Article
Language:English
Published: Society of Medical Biochemists of Serbia, Belgrade 2025-01-01
Series:Journal of Medical Biochemistry
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582502269G.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850263483530084352
author Gao Shouda
Zhang Lijun
Liu Liyan
Meng Jiayin
author_facet Gao Shouda
Zhang Lijun
Liu Liyan
Meng Jiayin
author_sort Gao Shouda
collection DOAJ
description Background: This study aimed to compare the efficacy of Denosumab (DEN) versus Zoledronic acid (ZOL) in treating patients with osteoporotic vertebral compression fractures (OVCF) after percutaneous kyphoplasty (PKP). Methods: In this study, 128 OVCF patients who underwent PKP in our hospital from June 2019 to August 2022 were selected and randomized into a DEN group treated with DEN and a ZOL group treated with ZOL. Bone mineral density (BMD), bone metabolism, pain, and lumbar mobility were compared between the two groups before and after treatment, and the anterior vertebral height and local kyphotic angle were measured. Finally, the one-year refracture rate and treatment cost were counted. Results: The two groups showed no notable difference in pain, lumbar mobility, anterior vertebral height, and local kyphotic angle after treatment (P>0.050). BMD was higher in the DEN group at 6 and 12 months after treatment, while b isomer of C-terminal telopeptide of type I collagen (b-CTX) was lower (P<0.050). No statistical inter-group difference was identified in the one-year re-fracture rate (P>0.050), while the total treatment cost was lower in the DEN group compared with ZOL group (P<0.050). Conclusions: DEN and ZOL effectively improve the prognosis of OVCF patients after PKP, but DEN can more significantly improve BMD and bone metabolism with higher economic benefits.
format Article
id doaj-art-f6aca4ebcce941cea6ff0653be29fa85
institution OA Journals
issn 1452-8258
1452-8266
language English
publishDate 2025-01-01
publisher Society of Medical Biochemists of Serbia, Belgrade
record_format Article
series Journal of Medical Biochemistry
spelling doaj-art-f6aca4ebcce941cea6ff0653be29fa852025-08-20T01:54:57ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662025-01-0144226927610.5937/jomb0-520841452-82582502269GA comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fracturesGao Shouda0Zhang Lijun1Liu Liyan2Meng Jiayin3The Fifth People's Hospital of Jinan, Department of Orthopedics, Jinan, ChinaThe Fifth People's Hospital of Jinan, Department of Orthopedics, Jinan, ChinaThe Fifth People's Hospital of Jinan, Department of Nephropathy, Jinan, ChinaJinan Second People's Hospital, Department of Pharmaceutical, Jinan, ChinaBackground: This study aimed to compare the efficacy of Denosumab (DEN) versus Zoledronic acid (ZOL) in treating patients with osteoporotic vertebral compression fractures (OVCF) after percutaneous kyphoplasty (PKP). Methods: In this study, 128 OVCF patients who underwent PKP in our hospital from June 2019 to August 2022 were selected and randomized into a DEN group treated with DEN and a ZOL group treated with ZOL. Bone mineral density (BMD), bone metabolism, pain, and lumbar mobility were compared between the two groups before and after treatment, and the anterior vertebral height and local kyphotic angle were measured. Finally, the one-year refracture rate and treatment cost were counted. Results: The two groups showed no notable difference in pain, lumbar mobility, anterior vertebral height, and local kyphotic angle after treatment (P>0.050). BMD was higher in the DEN group at 6 and 12 months after treatment, while b isomer of C-terminal telopeptide of type I collagen (b-CTX) was lower (P<0.050). No statistical inter-group difference was identified in the one-year re-fracture rate (P>0.050), while the total treatment cost was lower in the DEN group compared with ZOL group (P<0.050). Conclusions: DEN and ZOL effectively improve the prognosis of OVCF patients after PKP, but DEN can more significantly improve BMD and bone metabolism with higher economic benefits.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582502269G.pdfosteoporotic vertebral compression fracturesserum bone alkaline phosphatase (bap)total procollagen type 1 amino-terminal propeptide (tp1np)bone gamma carboxy-glutamic acid containing proteins (bgp)denosumabzoledronic acidbone mineral densityclinical safetyeconomic benefits
spellingShingle Gao Shouda
Zhang Lijun
Liu Liyan
Meng Jiayin
A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
Journal of Medical Biochemistry
osteoporotic vertebral compression fractures
serum bone alkaline phosphatase (bap)
total procollagen type 1 amino-terminal propeptide (tp1np)
bone gamma carboxy-glutamic acid containing proteins (bgp)
denosumab
zoledronic acid
bone mineral density
clinical safety
economic benefits
title A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
title_full A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
title_fullStr A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
title_full_unstemmed A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
title_short A comparative analysis of Denosumab and Zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
title_sort comparative analysis of denosumab and zoledronic acid effects on bone metabolism and bone mineral density in individuals with osteoporotic vertebral compression fractures
topic osteoporotic vertebral compression fractures
serum bone alkaline phosphatase (bap)
total procollagen type 1 amino-terminal propeptide (tp1np)
bone gamma carboxy-glutamic acid containing proteins (bgp)
denosumab
zoledronic acid
bone mineral density
clinical safety
economic benefits
url https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582502269G.pdf
work_keys_str_mv AT gaoshouda acomparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT zhanglijun acomparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT liuliyan acomparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT mengjiayin acomparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT gaoshouda comparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT zhanglijun comparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT liuliyan comparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures
AT mengjiayin comparativeanalysisofdenosumabandzoledronicacideffectsonbonemetabolismandbonemineraldensityinindividualswithosteoporoticvertebralcompressionfractures